Stu Needleman, Chief Commercial Officer at Piramal Pharma Solutions, discusses the Biosecure Act and other big trends shaking up the industry, including GLP-1s, consolidation in the CDMO sector, and sterile fill-finish. He tells us more about Piramal’s $80-million expansion in Kentucky and how the company is adapting to the changes in the market. Check out the video!
Receive the latest pharmaceutical news, personalities, education, and career development – weekly to your inbox.
August 18, 2026
10 min read
From collapsing legacy models to the rise of Chinese biotech, industry leaders are being forced to rethink how drugs are developed, funded, and brought to market
August 4, 2026
4 min read
A recent multimillion-dollar freezer failure highlights the urgent need for real-time visibility across the pharmaceutical supply chain
July 27, 2026
3 min read
AI can help formulation teams better predict performance and allocate resources, but proprietary data protections remain a critical bottleneck
July 15, 2026
8 min read
Daphne Smyth of Veristat on the rise of Chinese biopharma, regulatory realities, and what comes next